Tessier Maude
Known title: Chief Business OfficerCIK: 0001848534
Associated companies
Transaction History
| IMA | ▲ Buy | Option Exercise | 38,915 | $114K | 1/18/2022 | View on chart |
| IMA | ▲ Buy | Option Exercise | 24,606 | $102K | 1/18/2022 | View on chart |
| IMA | ▲ Buy | Option Exercise | 8,265 | $37K | 1/18/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 3, 2026
ImageneBio Reports Inducement Grants Under Nasdaq Rule
ImageneBio has disclosed new inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This filing is a standard corporate disclosure regarding compensation and does not report new clinical data or financial results. The stock is currently trading within its 52-week range, with an average analyst target of $18.00.
ImageneBio Reports Inducement Grants Under Nasdaq Rule. ImageneBio has disclosed new inducement grants in compliance with Nasdaq Listing Rule 5635(c)(4). This filing is a standard corporate disclosure regarding compensation and does not report new clinical data or financial results. The stock is currently trading within its 52-week range, with an average analyst target of $18.00.